All In Biotech

Drug Trial Radar · NCT06545929

Study of Sunobinop on Craving in Alcohol Use Disorder

A Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 2 Study to Evaluate Impact of Sunobinop (V117957) on Alcohol Craving in Subjects Diagnosed With Moderate to Severe Alcohol Use Disorder and Seeking Treatment

Last checked: Nov 19, 2026Latest source record: Jul 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

Jan 28, 2025

Primary completion

Jul 14, 2025

Study completion Jul 14, 2025

Sponsor

Lead sponsor
Knoa Pharma LLCIndustry
Sponsor type
Industry
Collaborators
Imbrium Therapeutics
First posted
Aug 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy of sunobinop compared to placebo on alcohol craving in subjects with moderate to severe alcohol use disorder and these subjects are seeking treatment.

Conditions

  • Alcohol Use Disorder

Interventions

  • SunobinopDrug

    1 tablet taken orally at bedtime

  • Placebo to match sunobinopDrug

    1 tablet taken orally at bedtime

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Alcohol Urge Questionnaire (AUQ)Time frame: Day 14

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ohio Clinical Trials

    Columbus, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.